XML 110 R95.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental Guarantor Information - Consolidating Statements of Cash Flows (Details) - USD ($)
$ in Thousands
12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2014
Condensed Financial Statements, Captions [Line Items]      
Net cash (used in) provided by operating activities $ 163,025 $ (81,049) $ (160,469)
Cash flows from investing activities:      
Capital expenditures (12,219) (15,964) (14,553)
Proceeds from sale of fixed assets 2,624 0 0
Investments in unconsolidated entities (4,241) (4,944) (5,218)
Return of capital from unconsolidated entities and marketable securities 1,142 24,245 1,703
Increases in restricted cash (5,852) (5,546) (15,608)
Decreases in restricted cash 30,348 29,586 1,645
Advances to/from subsidiaries 0 0 0
Net cash provided by (used in) investing activities 11,802 27,377 (32,031)
Cash flows from financing activities:      
Repayment of debt (828,221) (18,573) (307,602)
Proceeds from issuance of new debt 642,150 0 325,000
Repayment of borrowings from credit facility (90,000) (75,000) 0
Borrowings from credit facility 90,000 75,000 0
Debt issuance costs (11,246) (126) (5,490)
Other changes (222) (200) 287
Dividends paid   0  
Advances to/from subsidiaries 0 0 0
Net cash (used in) provided by financing activities (197,539) (18,899) 12,195
Decrease in cash and cash equivalents (22,712) (72,571) (180,305)
Cash and cash equivalents at beginning of period 251,583 324,154 504,459
Cash and cash equivalents at end of period 228,871 251,583 324,154
Consolidating Adjustments      
Condensed Financial Statements, Captions [Line Items]      
Net cash (used in) provided by operating activities 0 0 0
Cash flows from investing activities:      
Capital expenditures 0 0 0
Proceeds from sale of fixed assets 0    
Investments in unconsolidated entities 0 0 0
Return of capital from unconsolidated entities and marketable securities 0 0 0
Increases in restricted cash 0 0 0
Decreases in restricted cash 0 0 0
Advances to/from subsidiaries (203,701) (302,594) 78,951
Net cash provided by (used in) investing activities (203,701) (302,594) 78,951
Cash flows from financing activities:      
Repayment of debt 0 0 0
Proceeds from issuance of new debt 0   0
Repayment of borrowings from credit facility 0 0  
Borrowings from credit facility 0 0  
Debt issuance costs 0 0 0
Other changes 0 0 0
Dividends paid   0  
Advances to/from subsidiaries 202,393 300,876 (77,582)
Net cash (used in) provided by financing activities 202,393 300,876 (77,582)
Decrease in cash and cash equivalents (1,308) (1,718) 1,369
Cash and cash equivalents at beginning of period (3,192) (1,474) (2,843)
Cash and cash equivalents at end of period (4,500) (3,192) (1,474)
Beazer Homes USA, Inc.      
Condensed Financial Statements, Captions [Line Items]      
Net cash (used in) provided by operating activities (56,218) (388,584) (119,074)
Cash flows from investing activities:      
Capital expenditures 0 0 0
Proceeds from sale of fixed assets 0    
Investments in unconsolidated entities 0 0 0
Return of capital from unconsolidated entities and marketable securities 0 0 0
Increases in restricted cash (2,388) (2,982) (14,111)
Decreases in restricted cash 26,698 27,751 39
Advances to/from subsidiaries 203,690 302,569 (78,951)
Net cash provided by (used in) investing activities 228,000 327,338 (93,023)
Cash flows from financing activities:      
Repayment of debt (819,044) (8,703) (305,061)
Proceeds from issuance of new debt 642,150   325,000
Repayment of borrowings from credit facility (90,000) (75,000)  
Borrowings from credit facility 90,000 75,000  
Debt issuance costs (11,246) (126) (5,490)
Other changes (222) (200) 287
Dividends paid   500  
Advances to/from subsidiaries 0 21 0
Net cash (used in) provided by financing activities (188,362) (8,508) 14,736
Decrease in cash and cash equivalents (16,580) (69,754) (197,361)
Cash and cash equivalents at beginning of period 232,226 301,980 499,341
Cash and cash equivalents at end of period 215,646 232,226 301,980
Guarantor Subsidiaries      
Condensed Financial Statements, Captions [Line Items]      
Net cash (used in) provided by operating activities 219,401 307,668 (41,429)
Cash flows from investing activities:      
Capital expenditures (12,219) (15,964) (14,553)
Proceeds from sale of fixed assets 2,624    
Investments in unconsolidated entities (4,241) (4,944) (5,218)
Return of capital from unconsolidated entities and marketable securities 1,142 24,245 1,703
Increases in restricted cash (3,464) (2,564) (1,497)
Decreases in restricted cash 3,650 1,835 1,606
Advances to/from subsidiaries 0 0 0
Net cash provided by (used in) investing activities (12,508) 2,608 (17,959)
Cash flows from financing activities:      
Repayment of debt (9,177) (9,870) (2,541)
Proceeds from issuance of new debt 0   0
Repayment of borrowings from credit facility 0 0  
Borrowings from credit facility 0 0  
Debt issuance costs 0 0 0
Other changes 0 0 0
Dividends paid   0  
Advances to/from subsidiaries (202,393) (300,897) 77,639
Net cash (used in) provided by financing activities (211,570) (310,767) 75,098
Decrease in cash and cash equivalents (4,677) (491) 15,710
Cash and cash equivalents at beginning of period 21,543 22,034 6,324
Cash and cash equivalents at end of period 16,866 21,543 22,034
Non-Guarantor Subsidiaries      
Condensed Financial Statements, Captions [Line Items]      
Net cash (used in) provided by operating activities (158) (133) 34
Cash flows from investing activities:      
Capital expenditures 0 0 0
Proceeds from sale of fixed assets 0    
Investments in unconsolidated entities 0 0 0
Return of capital from unconsolidated entities and marketable securities 0 0 0
Increases in restricted cash 0 0 0
Decreases in restricted cash 0 0 0
Advances to/from subsidiaries 11 25 0
Net cash provided by (used in) investing activities 11 25 0
Cash flows from financing activities:      
Repayment of debt 0 0 0
Proceeds from issuance of new debt 0   0
Repayment of borrowings from credit facility 0 0  
Borrowings from credit facility 0 0  
Debt issuance costs 0 0 0
Other changes 0 0 0
Dividends paid   (500)  
Advances to/from subsidiaries 0 0 (57)
Net cash (used in) provided by financing activities 0 (500) (57)
Decrease in cash and cash equivalents (147) (608) (23)
Cash and cash equivalents at beginning of period 1,006 1,614 1,637
Cash and cash equivalents at end of period $ 859 $ 1,006 $ 1,614